A review of continuous renal replacement therapy

Patients in the Intensive Care Unit commonly develop acute renal failure (ARF). The kidneys are rarely the only organs failing in these patients. Frequently ARF is part of multiple organ dysfunction syndrome. The choice of dialytic therapy should consider, not only the efficacy of the therapy, but also the undesirable effects such therapy may have on the other failing organs. Intermittent Haemodialysis and Peritoneal Dialysis were the conventional forms of dialysis available. Both are associated with complications which may make them unsuitable for use in the haemodynamically unstable, hypercatabolic patients, seen in the Intensive Care setting. Continuous Renal Replacement Therapy (CRRT) has been introduced in many Intensive Care Units to provide a more stable, flexible form of dialysis. The purpose of this article is to give an overview of the various forms of CRRT and to discuss the advantages of this form of therapy.

Acute continuous hemodiafiltration: a prospective study of 110 patients and a review of the literature

One hundred ten critically ill patients with acute renal failure receiving acute continuous hemodiafiltration (ACHD) in our intensive care unit were studied prospectively. Acute continuous hemodiafiltration consisted either of continuous arteriovenous hemodiafiltration or of continuous veno-venous hemodiafiltration, and was used for 17,817 hours (mean duration of patient treatment, 161.9 hours), resulting in a fall from a mean pre-ACHD urea of 35.7 mmol/L to a plateau value of 16.8 mmol/L at 72 hours of treatment. The mean urea clearance achieved was 24.9 mL/min. Eighty of these patients (72.7%) were receiving artificial ventilation at the time of ACHD and 45 (40.9%) had more than four failing organs. The mean APACHE II score was 27.7. Despite the degree of illness severity, 42 patients (32.2%) survived to discharge from hospital. The use of ACHD was associated with hemodynamic stability, rapid normalization of electrolytes, and the ability to freely administer drugs, blood, and/or blood products. It also allowed for maintenance of an aggressive, nitrogen-rich, nutritional regimen. Support of these critically ill patients with acute renal failure using ACHD was achieved safely and without the employment of additional dialysis-trained nursing staff. Our own experience and a review of the available literature strongly suggest that the advantages associated with the use of ACHD therapies are clinically significant and support the view that ACHD is a modality of renal replacement most suited to critically ill patients with acute renal failure.

Continuous venovenous hemofiltration

Continuous venovenous hemofiltration (CVVH) is a technique characterized by a venovenous circuit and a pump to perfuse the hemofilter. CVVH is suited to individualization of ultrafiltration and solute clearance in patients with acute renal failure and volume overload, specifically when there is impaired cardiovascular function or where arterial access is problematic. Examples, indications and relative advantages of this and other dialytic modalities are discussed.

Extracorporeal treatment of acute renal failure in the intensive care unit: a critical view

Acute renal failure in critically ill patients is seldom an isolated problem but is more usually associated with multiple organ failure. When choosing an extracorporeal kidney replacement therapy, these other failing organs must be taken into account. Therefore the choice of an artificial kidney in patients requiring intensive care depends on both the efficacy of the technique and its possible adverse effects on cerebral, pulmonary and cardiovascular function. The most important pathogenic factors in the development of dysequilibrium syndromes, arterial hypoxemia and hypotension are treatment timing, diffusive solute transfer, bio-incompatible membranes and some specific dialysate components (buffer, electrolyte concentrations). It is important to understand the mechanisms by which these factors exert their adverse effects. Application of these pathophysiological mechanisms to the cardiopulmonary and neurologic status of the individual patient permits the prediction of their clinical outcome. This approach will lead to individualised treatment selection, thereby avoiding deleterious side-effects without loss of efficacy.